Glucose Release as a Response to Glucagon in Rat Hepatocyte Culture: Involvement of NO Signaling

H. FARGHALI[1], J. HODIS[1], N. KUTINOVÁ-CANOVÁ[1], P. POTMĚŠIL[2], E. KMONÍČKOVÁ[2], Z. ZÍDEK[2]

[1]Institute of Pharmacology, First Faculty of Medicine, Charles University, Prague, [2]Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic

Summary

Glucagon and α-adrenergic-induced glycogenolysis is realized *via* the agonist/adenylyl cyclase/cAMP/protein kinase signaling pathway or *via* the activation of phosphorylase kinase by the mobilized calcium that supports the inhibition of glycogen synthase, respectively. The role of nitric oxide (NO) in this process has not been extensively studied. The present work was directed to the question whether NO is produced during glucagon-induced glycogenolysis in rat hepatocyte in a similar way like α-adrenoceptor stimulation. Glycogen-rich hepatocyte cultures were used. NO production (NO_2^-) was assessed under the influence of glucagon, dibutyryl cyclic AMP (db-cAMP), forskolin, the nitric oxide synthase (NOS) inhibitors N^ω-nitro-L-arginine methyl ester (L-NAME) and aminoguanidine, and the NO donor S-nitroso-N-acetyl penicillamine (SNAP). Inducible NOS (iNOS) mRNA was examined by reverse transcription-polymerase chain reaction. Glycogenolysis was followed up by estimation of medium glucose levels. The amount of glucose and NO_2^- released by glycogen-rich hepatocytes was increased as a result of glucagon, db-cAMP, forskolin and SNAP treatments. iNOS gene expression was upregulated by glucagon. Glycogenolysis that occurs through glucagon receptor stimulation involves NO production downstream of transduction pathways through an isoform of NO synthase. The present and previous studies document possible involvement of NO signaling in glycogenolytic response to glucagon and adrenergic agonists in hepatocytes.

Key words

Nitric oxide • Glucagon • Glycogenolysis • Hepatocytes

Corresponding author

H. Farghali, Institute of Pharmacology, First Faculty of Medicine, Charles University, Albertov 4, 128 00 Prague 2, Czech Republic. Fax: +420 224968106. E–mail: hfarg@lf1.cuni.cz

Introduction

It is established that the liver plays a central role in the control of glucose production and that disturbances, which occur in some metabolic diseases, could indicate the presence of alterations in glycogen deposition of various causes with either increase or decrease in liver glycogen. The molecular mechanisms of increased glucose production to identify potential therapeutic targets were reviewed (Proietto and Andrikopoulos 2004, Klover and Mooney 2004) and it has been recognized that hepatocytes are critical for glucose homeostasis. The signaling pathways that participate in hormone-induced glycogen degradation are documented (Decker 1990, Huber and Keppler 1990, Borgs *et al.* 1996).

Glucagon raises cyclic AMP (cAMP) levels that activate protein kinase A (PKA) and this in turn leads to the activation of phosphorylase and glycogen breakdown. At the same time, PKA phosphorylates and helps to inactivate glycogen synthase. Moreover, epinephrine through its α_1-adrenergic receptors regulates hepatic glycogenolysis in some animal species. Altogether, glucagon and epinephrine on the one hand, and insulin on the other, determine the status of glycogen store. The regulation of glycogenolysis in hepatocytes by both hormones appears to be equally important under physiological and pathological conditions (Van Ermen and Fraeyman 1994, Moriyama *et al.* 1997, Shiroyama *et al.* 1998, Fabbri *et al.* 1999, Vardanega-Peicher *et al.* 2000, Manzl *et al.* 2002, Kalamidas *et al.* 2002).

Although the pathways that modulate glycogen level in the liver have been fairly well elucidated, the role

of nitric oxide (NO) in this process is not extensively studied. In our previous work, we found that glycogenolysis in rat hepatocytes that occurs through α-adrenergic stimulation involve NO production (Hodis *et al.* 2007). Indeed, NO exerts functional regulatory effects in all organs, tissues and cells, which were examined including the liver (Muriel 2000, Moreau 2002, Chang *et al.* 2004, Harbrecht *et al.* 2004, Voleti and Agrawal 2006). It was reported that NO affects glycogen and glucose homeostasis (Horton *et al.* 1994a, Horton *et al.* 1994b, Stadler *et al.* 1995, Borgs *et al.* 1996, Sugita *et al.* 2002). The data available suggest that glucagon may participate in the *in vivo* regulation of hepatic inducible nitric oxide synthase (iNOS) expression after proinflammatory stimuli. Nevertheless, it is not yet clear to which extent NO is involved in the modulation of glycogenolytic pathways. The present work was, therefore, directed to extend our previous observation by the study that shed more light on whether NO is produced during glucagon-induced glycogenolysis in rat hepatocyte cultures in a similar way like adrenergic stimulation (Hodis *et al.* 2007). The glycogen-rich rat hepatocytes in culture were used for glycogenolysis studies under glucagon, dibutyryl cyclic AMP (db-cAMP), forskolin, and the NO donor S-nitroso-N-acetyl penicillamine (SNAP). NO production was assessed under various treatments.

Materials and Methods

Chemicals

Glucagon was obtained in ampoules (Glucagen 1 mg HypoKit inj. sic.) from Novo Nordisk, Denmark. Sulfanilic acid, N-(1-naphtyl)ethylendiamine dihydrochloride, dibutyryl cyclic AMP sodium-potassium salt (db-cAMP), N^{ω}-nitro-L-arginine methyl ester (L-NAME), aminoguanidine, S-nitroso-N-acetyl penicillamine (SNAP), forskolin (7β-acetoxy-1α,6β,9α-trihydroxy-8,13-epoxy-labd-14-en-11-one), dimethyl sulfoxide (DMSO), HEPES, Dulbecco's phosphate buffered saline, William′s medium E, gentamycin, L-glutamine and fetal bovine serum (FBS) and bovine serum albumin fraction V (BSA), were obtained from Sigma-Aldrich (Prague, Czech Republic). Collagenase and glucose assay kit were obtained from Sevapharma and Vian Diagnostika (Prague, Czech Republic), respectively. A commercial kit for nitrite/nitrate colorimetric detection was obtained from Roche Diagnostic (Prague). Other chemicals were obtained from standard sources.

Animals

Male rats of Wistar strain (Velaz-Lysolaje, 200-250 g body weight) received humane care and the study procedures were carried out in accordance with the Animal Care Guidelines of the First Faculty of Medicine.

Isolation and preparation of glycogen-rich hepatocyte culture

Hepatocytes were isolated from anesthetized rats by a standard two-phase collagenase perfusion method as previously reported (Farghali *et al.* 1994). After isolation, cell viability was at least 90 % as assessed by trypan blue. The preparation of glycogen-rich hepatocytes was performed according to Shiroyama *et al.* (1998) with minor modification (Hodis *et al.* 2007). Hepatocytes from untreated animals were plated into collagen-coated cell culture dishes and maintained at 37 °C, 95 % air, and 5 % CO_2 in William's medium E, supplemented with gentamycin, L-glutamine, 10 mM HEPES, 6 % FBS, 2×10^{-7} M insulin and 20 mM glucose overnight. The produced glycogen-rich cells were used to determine glycogenolytic glucose release. High glycogen content of hepatocytes was confirmed biochemically and histochemically (Shiroyama *et al.* 1998). This model proved to be convenient for the study of glycogenolysis by glucose release since there are no substrates as lactate, amino acids or other types of sugar necessary for gluconeogenesis.

Drug treatments and measurement of glycogenolytic glucose release

The medium of the glycogen-rich hepatocytes was changed to glucose-free Dulbecco's phosphate buffered saline just before the relevant treatment. Glucagon (0.5-10 µg/ml) was added to the glucose-free Dulbecco's phosphate buffered saline medium in culture. Cultured hepatocytes were treated with forskolin (50 µM), db-cAMP (1 mM) or SNAP (25 and 250 µM). DMSO at final concentration of less than 1 % (v/v) used as the solvent for some compounds (e.g. forskolin) was found to be without any effect on the measured parameters. The time course of glucose release was followed till 60 min of incubation. The estimation of medium glucose levels was done spectrophotometricaly according to the enzymatic glucose assay kit instructions from Vian Diagnostika (Prague, Czech Republic).

Determination of nitric oxide production

NO production from the cells into the medium was measured in appropriate time intervals as indicated in

the Results. NO production was determined by measuring the levels of its oxidation products NO_2^- and NO_3^- in the culture medium. This was detected colorimetrically (540 nm) by Griess reagent and/or by nitrite/nitrate colorimetric method from Roche Diagnostic. The nitrite levels were extrapolated from $NaNO_2$ calibration curve.

Reverse transcriptase-polymerase chain reaction for iNOS expression

The 24-h cultured hepatocytes were used for reverse transcriptase-polymerase chain reaction (RT-PCR) without glucagon or under glucagon or L-NAME + glucagon treatment. RNA from hepatocytes was isolated by the standard procedure by Quiagen® RNeasy mini kit as described earlier for iNOS (Farghali *et al.* 2002). Total RNA content was finally measured by spectrophotometry-Eppendorf® BioPhotometer, RNA purity was counted from absorption rate of 260/280 nm respectively. The total RNA was amplified and reverse transcribed into cDNA *via* RT-PCR. 2.3 µl of cDNA formed was treated with PCR reaction mix after following protocol: Mix (47.7 µl) = H_2O 33.6 µl + red buffer 5.0 µl + black $MgCl_2$ 4.0 µl + primer F 0.3 µl + primer R 0.3 µl + blue NTP 1.0 µl + yellow enhancer 1.0 µl + Taq® polymerase 2.5 µl. Cycler´s conditions being: 2´94°//25x (20´´94°/10´´59°1´72°)//10´72°. The primers were constructed as described before (Farghali *et al.* 2002) 5´-GGC AGA CTG GAT TTG GCT GGT C-3´; R 5´- AGG TGT TCC CCA GGT AGG TAG C-3´, comprising exon-intron DNA boundaries eliminating external contaminating DNA to be involved into PCR reaction. The relative level of iNOS mRNA expression was determined after normalization to the β-actin signal to account for variability in the amount of RNA that had been extracted from cells.

Amplified samples were run on agarose gels and stained with ethidium bromide. Images were captured using a monochrome camera and signal density measured by Kodak 1D Image Analysis Software Version 3.0 and compared to control sample.

Statistical analysis

In most of the experiments, the protein content of hepatocytes was estimated and was found to be variable per culture plate. Therefore, control culture plate was done for every single experiment. The experiments were performed at a minimum 6-8 times in triplicates (means of 18-24 values ± S.E.M.) with blind samples as the media background. The statistical significance of difference of mean scores was determined using the unpaired Student's t-test or ANOVA where appropriate. $P \le 0.05$ values were considered statistically significant.

Results

Figure 1 demonstrates that the amount of glucose and nitrite released by glycogen-rich hepatocytes was significantly increased as a function of incubation time by glucagon (1 µg/ml) treatment. These data show that at sampling times 30 and 60 min, both glucose and nitrite levels were higher under glucagon treatment as compared to control treatment. The effects were not evident at time 120 min (data are not shown). Sampling times of 30 and 60 min were, therefore, chosen for the subsequent experiments. In hepatocyte culture, treatment with glucagon increased iNOS gene expression (measured by RT-PCR) by about twofold (Fig. 2). This figure shows a photograph of an agarose gel of iNOS mRNA levels, where iNOS mRNA was detected in non-induced control hepatocytes. Following the treatment with glucagon, there was an intense PCR product of iNOS that was observed after 60 min exposure of hepatocytes in culture. It is clear that L-NAME did not significantly affect the level of iNOS mRNA which was expected because L-NAME is an inhibitor of NOS *per se* (i.e. post-translation effect).

Table 1 shows the relative effect of five different treatments (30 and 60 min incubation) on nitrite production and glucose release in hepatocyte culture. Both aminoguanidine and L-NAME at high concentrations were able to decrease significantly NO production (measured as nitrite) and glycogenolysis (measured as glucose) induced by glucagon. This effect was measurable and significant in most cases at 30 and 60 min with aminoguanidine being more potent. Moreover, Table 1 demonstrates that both db-cAMP and the specific activator of adenylyl cyclase, forskolin, significantly increased both glucose release and nitrite levels.

The effects of exogenously delivered NO (SNAP addition) on glucose release and nitrite levels is demonstrated in Figure 3. As expected, SNAP at 25 and 250 µM concentrations in the culture medium produced highly significant concentration-dependent increase in total nitrite levels as compared to control treatment (Fig. 3B). In addition, SNAP significantly increased basal glucose production 30 min after incubation when compared to control values (Fig. 3A).

Fig. 1. Glucose **(A)** and nitrites **(B)** released to culture medium by glycogen-rich hepatocytes under control conditions and glucagon (1 µg/ml) treatment after 30 and 60 min. Values are expressed as means ± S.E.M. * Significantly different from the respective control group (P≤0.05).

Fig. 2. A representative photograph of an agarose gel of RT-PCR demonstrating iNOS mRNA levels, where columns depict iNOS mRNA ladder with 386 bp and cultured hepatocytes under: 1) no treatment (control), 2) 1 µg/ml glucagon, 3) 1 µg/ml glucagon + 10 mM L-NAME treatment. The graph illustrates the quantified signal density of iNOS PCR products of treated hepatocytes compared to control sample. Results were recorded after 60 min incubation.

Discussion

The role of NO in a number of liver functions is being investigated intensively. It was suggested that nitric oxide synthases are players in the pathophysiology of some hepatic diseases (Moreau 2002). In several other reports, it was found that NO affects glycogen and glucose homeostasis (Horton *et al.* 1994a,b, Stadler *et al.* 1995, Borgs *et al.* 1996, Sugita *et al.* 2002). However, it is still not clear how NO is involved in the modulation of glycogenolytic pathways under physiological conditions. Moreover, there are data which indicate that glucagon may participate in the *in vivo* regulation of hepatic iNOS expression after proinflammatory stimuli (Harbrecht *et al.* 2004). The current investigation was motivated by our previous finding on the involvement of NO release in the activation of hepatocyte glycogenolysis after α-adreno-ceptor stimulation (Hodis *et al.* 2007). The importance of the present study stems from the fact that liver has a central role in the control of glucose production and that the hepatocytes are the main players. Therefore, research is directed towards finding out

pharmacological means that modulates hepatocyte signaling pathways with consequent alterations in glycogenolysis or gluconeogenesis.

The present data demonstrate that glucagon-stimulated glycogenolysis in hepatocytes is accompanied by an increase in NO release. The present findings together with our previous ones (Hodis *et al.* 2007) demonstrate that NO is released, probably, as a common denominator signal during glycogenolysis as revealed for both α-adrenergic- and glucagon-agonistic effects.

The measurement of glycogenolysis was carried out in glycogen-rich hepatocytes prepared according to Shiroyama *et al.* (1998). These cells are suitable for determination of agonist-induced glycogenolytic glucose release in glucose-free incubation medium. Significantly higher nitrite levels produced by glucagon were observed 60 min after the incubation of hepatocytes in culture. The effect of glucagon on NO production is expected to occur at later time than the effect on glucose. This is due to the fact that NO is not directly measured but rather its oxidation product in the medium, i.e. nitrite/nitrate, which needs time to be formed from NO.

Taken together, it seems that glucagon- and α-adrenergic-induced glycogenolysis that are mediated *via* the agonist/adenylyl cyclase/PKA cascade and

Table 1. The relative effect of incubation (30 and 60 min) with glucagon (1 μg/ml), aminoguanidine (AG, 10 mM) + glucagon, N^{ω}-nitro-L-arginine methyl ester (L-NAME, 10 mM) + glucagon, dibutyryl cAMP (db-cAMP, 1 mM) and forskolin (50 μM) treatments on nitrite production and glucose release from hepatocytes in culture (mean values ± S.E.M. of 20-24 cultures).

Treatments				
	Percent of control[a] ± SEM			
	Nitrite (μM) after		**Glucose (μM) after**	
	30 min	**60 min**	**30 min**	**60 min**
Glucagon	114±15	133±11*	267±25*	148±12*
AG + glucagon	75±5*	53±5*	90±15	117±10
L-NAME + glucagon	150±8*	76±6*	191±30*	150±15*
db-cAMP	120±10*	160±8*	140±10*	90±25
Forskolin	116±4*	120±3*	147±13*	75±8*

* Significantly different from control (P≤0.05).
[a] Percent of the amount of produced nitrite or glucose in treated culture per the amount in appropriate control culture (treated/control x 100).

Fig. 3. The effect of S-nitroso-N-acetyl penicillamine (SNAP, 25 and 250 μM) treatment on glucose **(A)** and nitrite **(B)** release from glycogen-rich hepatocytes cultured for 30 and 60 min. Values are expressed as means ± S.E.M. * Significantly different from the respective control group (P≤0.05).

cAMP signaling pathway or *via* the activation of phosphorylase kinase by the mobilized calcium that is aided by the inhibition of glycogen synthase (Dempsey *et al.* 2000), may involve downstream NO production. This is further evidenced by the adenylyl cyclase activator, forskolin, and the stable congener to cAMP, db-cAMP, because both of them produce qualitatively identical effects on glycogenolysis and NO production as glucagon. Moreover, we added SNAP at two concentrations to hepatocyte culture, and we observed dose-dependent increase in basal glycogenolysis. Accordingly, we may suggest that endogenous NO produced downstream of agonist/receptor signal transduction pathway and coupling through an isoform of NOS, plays a role in glycogenolysis. This is further supported by our data demonstrating that aminoguanidine (and to some extent also L-NAME) were able to partially inhibit the glycogenolytic effect of glucagon and epinephrine. Moreover, iNOS mRNA was significantly enhanced by both glucagon (present data) and epinephrine (Hodis *et al.* 2007). The present data do not rule out the involvement of either NOS isoform in contributing to the glycogenolytic signaling pathway(s) in isolated cultured hepatocytes. Recently, we have found a similar involvement of NO signaling during β-adrenergic lipolysis in rat white adipocytes (Kutinova-Canova *et al.* 2006) indicating the widespread role of

NO in various pathophysiological processes of the liver as well as other well established functions in other organs and tissues.

In summary, our studies may suggest that under the present experimental conditions, endogenous NO is produced downstream of glucagon- receptor or α-adreno-ceptor signal transduction pathways through an isoform of NO synthases and that it plays a role in glocogenolysis. This is supported by our findings that: 1) glucagon and epinephrine increased NO and simultaneously stimulated glycogenolysis, 2) prazosin (a selective α-adrenergic blocker) but not propranolol (non selective β-adrenergic blocker) was able to inhibit the glycogenolytic effect of α-adrenergic agonists concomitantly with a reduction of the amount of nitrite formed in the medium, 3) both glucagon and epinephrine increased iNOS mRNA, 4) db-cAMP and the adenlyl cyclase activator, forskolin, stimulated both nitrite production and glucose release, 5) NO exogenously delivered through SNAP to hepatocyte culture stimulated glycogenolysis, and 6) inhibitors of NO synthase reduced nitrite production and glycogenolysis in cultured rat hepatocytes. However, more studies are needed to further clarify of NO role in glycogenolysis.

References

BORGS M, BOLLEN M, KEPPENS S, YAP SH, STALMANS W, VANSTAPEL F: Modulation of basal hepatic glycogenolysis by nitric oxide. *Hepatology* **23**: 1564-1571, 1996.

CHANG K, LEE SJ, CHEONG I, BILLIAR TR, CHUNG HT, HAN JA, KWON YG, HA KS, KIM YM: Nitric oxide suppresses inducible nitric oxide synthase expression by inhibiting post-translational modification of 1 κB. *Exp Mol Med* **36**: 311-324, 2004.

DECKER K: Biologically-active products of stimulated liver macrophages (Kupffer cells). *Eur J Biochem* **192**: 245-261, 1990.

DEMPSEY EC, NEWTON AC, MOCHLY ROSEN D, FIELDS AP, RAYLAND ME, INSEL PA, MESSING RO: Protein kinase C isozymes and the regulation of diverse cell responses. *Am J Physiol* **279**: L429-L438, 2000.

FABBRI E, BUZZI M, BIONDI C, CAPUZZO A: Alpha-adrenoceptor mediated glucose release from perifused catfish hepatocytes. *Life Sci* **65**: 27-35, 1999.

FARGHALI H, KAMENÍKOVÁ L, HYNIE S: Preparation of functionally active immobilized and perfused mammalian cells: an example of hepatocyte bioreactor. *Physiol Res* **43**: 121-125, 1994.

FARGHALI H, CANOVÁ N, GAIER N, LINCOVÁ D, KMONÍČKOVÁ E, STREŠTÍKOVÁ P, MAŠEK K: Inhibition of endotoxemia-induced nitric oxide synthase expression by cyclosporin A enhances hepatocyte injury in rats: amelioration by NO donors. *Int Immunopharmacol* **2**: 117-127, 2002.

FRAEYMAN N, VAN ERMEN A: Influence of aging on the beta- and glucagon-receptor-mediated glycogenolysis in rat hepatocytes. *Mech Ageing Dev* **70**: 115-126, 1993.

HARBRECHT BG, PERPETUA M, FULMER M, ZHANG BC: Glucagon regulates hepatic inducible nitric oxide synthesis in vivo. *Shock* **22**: 157-162, 2004.

HODIS J, KUTINOVÁ-CANOVÁ N, POTMĚŠIL P, KAMENÍKOVÁ L, KMONÍČKOVÁ E, ZÍDEK Z, FARGHALI H: The role of adrenergic agonists on glycogenolysis in rat hepatocyte culture and possible involving of NO. *Physiol Res* **56**: 419-425, 2007.

HORTON RA, KNOWLES RG, TITHERADGE MA: Endotoxin causes changes in hepatic nitric-oxide synthesis, gluconeogenesis, and flux through phosphoenolpyruvate carboxykinase. *Biochem Biophys Res Commun* **204**: 659-665, 1994a.

HORTON RA, CEPPI ED, KNOWLES RG, TITHERADGE MA: Inhibition of hepatic gluconeogenesis by nitric oxide – a comparison with endotoxic shock. *Biochem J* **299**: 735-739, 1994b.

HUBER M, KEPPLER D: Eicosanoids and the liver. *Prog Liver Dis* **9**: 117-141, 1990.

KALAMIDAS SA, KOTOULAS OB, HANN AC: Studies on glycogen autophagy: effects of phorbol myristate acetate, ionophore A23187, or phentolamine. *Microsc Res Tech* **57**: 507-511, 2002.

KLOVER PJ, MOONEY RA: Hepatocytes: critical for glucose homeostasis. *Int J Biochem Cell Biol* **36**: 753-758, 2004.

KUTINOVÁ-CANOVÁ N, LINCOVÁ D, KMONÍČKOVÁ E, KAMENÍKOVÁ L, FARGHALI H: Nitric oxide production from rat adipocytes is modulated by β_3-adrenergic receptor agonists and is involved in a cyclic AMP-dependent lipolysis in adipocytes. *Nitric Oxide-Biol Chem* **14**: 200–211, 2006.

MANZL C, SCHUBERT M, SCHWARZBAUM PJ, KRUMSCHNABEL G: Effects of chemical anoxia on adrenergic responses of goldfish hepatocytes and the contribution of alpha- and beta-adrenoceptors. *J Exp Zool* **292**: 468-476, 2002.

MOREAU R: Are nitric oxide synthases new players in the pathopysiology of fulminant hepatic failure? *J Hepatol* **37**: 678-680, 2002.

MORIYAMA M, NAKANISHI Y, TSUYAMA S, KANNAN Y, OHTA M, SUGANO T: Change from beta- to alpha-adrenergic glycogenolysis induced by corticosteroids in female rat liver. *Am J Physiol* **273**: R153-R160, 1997.

MURIEL P: Regulation of nitric oxide synthesis in the liver. *J Appl Toxicol* **20**: 189-195, 2000.

PROIETTO J, ANDRIKOPOULOS S: Molecular mechanisms of increased glucose production: Identifying potential therapeutic targets. *J Investig Med* **52**: 389-393, 2004.

SHIROYAMA K, MORIWAKI K, YUGE O: The direct effect of dopamine on glucose release from primary cultured rat hepatocytes. *In vivo* **12**: 527-529, 1998.

STADLER J, BARTON D, BEIL-MOELLER H, DIEKMANN S, HIERHOLZER C, ERHARD W, HEIDECKE CD: Hepatocyte nitric-oxide biosynthesis inhibits glucose output and competes with urea synthesis for L-arginine. *Am J Physiol* **268**: G183-G188, 1995.

SUGITA H, KANEKI M, TOKUNAGA E, SUGITA M, KOIKE C, YASUHARA S, TOMPKINS RG, JEEVENDRA M: Inducible nitric oxide synthase plays a role in LPS-induced hyperglycemia and insulin resistance. *Am J Physiol* **282**: E386-E394, 2002.

VAN ERMEN A, FRAEYMAN N: Desensitization of α_1-receptor, beta-receptor and glucagon-receptor in rat hepatocytes – influence of ageing. *Mech Ageing Dev* **75**: 45-58, 1994.

VARDANEGA-PEICHER M, LOPES G, LIMA FB, CURI R, NAKANO LC, BAZOTTE PB: Time sequence of changes in the responsiveness of glycogen breakdown to adrenergic agonists in perfused liver of rats with insulin-induced hypoglycemia. *Braz J Med Biol Res* **33**: 805-813, 2000.

VOLETI B, AGRAWAL A: Statins and nitric oxide reduce C reactive protein production while inflammatory conditions persist. *Mol Immunol* **43**: 891-896, 2006.